| Major bleeding | DAPT 12Mo | 0.65 (0.24, 1.29) | 0.67 (0.31, 1.37) | 0.58 (0.31, 1.13) | 0.76 (0.44, 1.25) | 1.53 (0.95, 2.75) | 1.54 (0.77, 4.24) | DAPT 1Mo + P2Y12 | 1.03 (0.37, 3.63) | 0.89 (0.36, 3.08) | 1.18 (0.49, 3.53) | 2.38 (1.05, 8.20) | 1.50 (0.73, 3.26) | 0.97 (0.28, 2.67) | DAPT 3Mo + ASA | 0.86 (0.34, 2.41) | 1.13 (0.46, 2.90) | 2.30 (1.00, 6.28) | 1.73 (0.89, 3.27) | 1.12 (0.32, 2.78) | 1.16 (0.41, 2.93) | DAPT 3Mo + P2Y12 | 1.31 (0.54, 2.88) | 2.66 (1.17, 6.36) | 1.32 (0.80, 2.27) | 0.85 (0.28, 2.02) | 0.89 (0.35, 2.18) | 0.76 (0.35, 1.85) | DAPT 6Mo | 2.04 (1.17, 3.93) | 0.65 (0.36, 1.05) | 0.42 (0.12, 0.95) | 0.44 (0.16, 1.00) | 0.38 (0.16, 0.85) | 0.49 (0.25, 0.85) | L-DAPT |
| Any bleeding | DAPT 12Mo | 0.75 (0.37, 1.16) | 0.73 (0.43, 1.21) | 0.58 (0.37, 0.87) | 0.72 (0.50, 1.00) | 1.53 (1.05, 2.12) | 1.33 (0.87, 2.72) | DAPT 1Mo + P2Y12 | 0.98 (0.50, 2.40) | 0.76 (0.43, 1.79) | 0.97 (0.55, 2.10) | 2.02 (1.18, 4.33) | 1.37 (0.82, 2.31) | 1.02 (0.42, 1.99) | DAPT 3Mo + ASA | 0.79 (0.41, 1.52) | 0.99 (0.53, 1.84) | 2.10 (1.09, 3.84) | 1.74 (1.15, 2.70) | 1.32 (0.56, 2.33) | 1.27 (0.66, 2.45) | DAPT 3Mo + P2Y12 | 1.26 (0.72, 2.16) | 2.67 (1.50, 4.52) | 1.39 (1.00, 1.99) | 1.04 (0.48, 1.80) | 1.01 (0.54, 1.90) | 0.79 (0.46, 1.39) | DAPT 6Mo | 2.10 (1.42, 3.10) | 0.65 (0.47, 0.96) | 0.50 (0.23, 0.85) | 0.48 (0.26, 0.91) | 0.37 (0.22, 0.67) | 0.48 (0.32, 0.71) | L-DAPT |
|
|
Results in the upper triangle are odds ratios with 95% confidence intervals from the network meta-analysis between the column defining intervention and row defining intervention. Significant results are in bold. L-DAPT refers to longer-term (>18 months) DAPT, DAPT 12Mo refers to 12-month DAPT, DAPT 6Mo refers to 6-month DAPT, DAPT 3Mo + ASA refers to 3-month DAPT followed by aspirin monotherapy, DAPT 3Mo + P2Y12 refers to 3-month DAPT followed by a P2Y12 receptor inhibitor monotherapy, and DAPT 1Mo + P2Y12 refers to 1-month DAPT followed by a P2Y12 receptor inhibitor monotherapy. DAPT indicates dual antiplatelet therapy.
|